Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Many calves develop pneumonia days before showing symptoms. Lung ultrasounds are helping veterinarians detect the hidden ...

Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...

Combination with investigational antibody-drug conjugate showed encouraging antitumor acti ...

The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn ...

Investing.com -- Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares fell 10% in after-hours trading Thursday following the company’s announcement of a proposed public offering of common stock.

HER2-targeted ADCs show ~50% response rates in pretreated endometrial cancer, with durable responses and manageable safety ...

Recurrent/metastatic EC has a poor long-term prognosis, and treatment options are limited beyond first line, said Pothuri.